Stuart Isaacson, MD, FAAN, defines the terminology of OFF episodes in Parkinson’s disease and what “OFF” means from a clinical perspective. Expert neurologist reviews manifestations of OFF episodes ...
Beginning with FDA news, the administration Xenon Pharmaceuticals has submitted a new drug application (NDA) to the FDA for ...
In recognition of International Ataxia Awareness Day, observed annually on NeurologyLive® reviews 6 investigational agents ...
Exploring the Link Between Football Players and ALS: Brian Lin, PhD In a recent Q&A interview, Brian Lin, PhD, research ...
Despite comedians’ assertions to the contrary, sex-associated headaches are not funny. But medications can help relieve or even prevent them. Comedians have long joked about spouses avoiding sex by ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
In this episode, host Lindsay Ross, MD, is joined by joined by Rachel Galioto, PhD, a Cleveland Clinic neuropsychologist ...
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted fast track designation to Scholar Rock’s apitegromab (Isembyld), a muscle-targeting therapy recently approved for the treatment of spinal muscular atrophy (SMA), for patients ...
Thirty-day headache history dominated feature importance; rolling mean severity alone contributed 37.6% and 30-day window features 56.3%, versus 11.1% for prodromal symptom features. Forecast ...
The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to ...
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results